Oculis (NASDAQ:OCS) Price Target Lowered to $45.00 at Guggenheim

Posted by on Jun 1st, 2026

Oculis (NASDAQ:OCS – Get Free Report) had its price objective decreased by Guggenheim from $75.00 to $45.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective would suggest a potential upside of 98.23% from the company’s previous close.

Several other research analysts also recently issued reports on OCS. JPMorgan Chase & Co. upped their price objective on Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a report on Monday, May 18th. Needham & Company LLC reduced their price objective on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Monday. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Finally, HC Wainwright dropped their target price on shares of Oculis from $47.00 to $26.00 and set a “buy” rating for the company in a research report on Monday. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Check Out Our Latest Analysis on Oculis

Oculis Stock Down 0.0%

Shares of OCS opened at $22.70 on Monday. The company has a market capitalization of $1.32 billion, a P/E ratio of -10.66 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. Oculis has a one year low of $16.00 and a one year high of $34.47. The business’s 50 day simple moving average is $27.68 and its 200-day simple moving average is $25.21.

Oculis (NASDAQ:OCS – Get Free Report) last announced its earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. As a group, sell-side analysts predict that Oculis will post -2.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Hedge funds have recently modified their holdings of the stock. Gildi lifeyrissjodur bought a new position in shares of Oculis in the 4th quarter valued at about $50,250,000. Aberdeen Group plc lifted its stake in Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after purchasing an additional 493,827 shares during the last quarter. Syquant Capital Sas acquired a new stake in Oculis in the 4th quarter valued at about $3,849,000. Simplify Asset Management Inc. acquired a new stake in Oculis in the 4th quarter valued at about $1,972,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

(Get Free Report)

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

Read More

Analyst Recommendations for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.